$182 million in Series C investment was received by San Mateo, California-based Bluejay Therapeutics, a business focused on the development of innovative pharmaceuticals.
Investots
- RA Capital Management
- T. Rowe Price
- Wellington Management
- Novo Holdings
- RiverVest Venture Partners
- Octagon Capital
- Arkin Bio Ventures
- HBM Healthcare Investments
- Unicorn Capital
- Frazier Life Sciences
Daniel Estes, a general partner at Frazier, joined Bluejay’s board of directors once the Series C funding was concluded.
Use of funds
With the money, the business hopes to advance the development of further potential candidates in Bluejay’s strong pipeline for the treatment of chronic hepatitis B and expedite the clinical development of BJT-778, a medication for chronic hepatitis D (HDV).
About Bluejay Therapeutics
Bluejay Therapeutics is a biopharmaceutical firm that focuses on developing therapies for liver and viral disorders. It is led by CEO Dr. Keting Chu. Developed for both chronic HBV and HDV, its primary program, BJT-778, is a completely human IgG1 monoclonal antibody against the hepatitis B surface antigen (anti-HBsAg mAb), with the potential to be the best in its class.
By neutralizing and eliminating HBV and HDV virions as well as reducing HBsAg-containing subviral particles, BJT-778 is intended to offer anti-HBV and anti-HDV advantages. This might aid in the restoration of a subject’s antiviral immunity and a functional cure for CHB. With the aim of attaining better rates of functional cure, Bluejay is also developing and progressing other cutting edge initiatives for chronic HBV, such as a liver focused transcript inhibitor (BJT-628) and a unique TLR9 agonist (Cavrotolimod).
